octahydro-[1]pyrindin-4-one | 92658-00-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: octahydro-[1]pyrindin-4-one
• 英文别名: Octahydro-[1]pyrindin-4-on；octahydro-4H-cyclopenta[b]pyridin-4-one；1,2,3,4a,5,6,7,7a-octahydrocyclopenta[b]pyridin-4-one
• CAS: 92658-00-9
• 化学式: C₈H₁₃NO
• mdl: MFCD03410245
• 分子量: 139.197
• InChiKey: ARUFORLDGOXCSV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.875
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  1-cyclopenten-1-yl-2-(diethylamino)ethyl ketone 在 1,4-二氧六环 、 氨 、 水 作用下， 生成 octahydro-[1]pyrindin-4-one
  参考文献：
  名称：

  Fuel economy and life-cycle cost analysis of a fuel cell hybrid vehicle

  摘要：

  The most promising vehicle engine that can overcome the problem of present internal combustion is the hydrogen fuel cell. Fuel cells are devices that change chemical energy directly into electrical energy without combustion. Pure fuel cell vehicles and fuel cell hybrid vehicles (i.e. a combination of fuel cell and battery) as energy sources are studied. Considerations of efficiency, fuel economy, and the characteristics of power output in hybridization of fuel cell vehicle are necessary, In the case of Federal Urban Driving Schedule (FUDS) cycle simulation, hybridization is more efficient than a pure fuel cell vehicle. The reason is that it is possible to capture regenerative braking energy and to operate the fuel cell system within a more efficient range by using battery.Life-cycle cost is largely affected by the fuel cell size, fuel cell cost, and hydrogen cost. When the cost of fuel cell is high, hybridization is profitable, but when the cost of fuel cell is less than 400 US$/kW. a pure fuel cell vehicle is more profitable. (C) 2002 Elsevier Science B.V. All rights reserved.

  DOI：

  10.1016/s0378-7753(01)00965-x

文献信息

• [EN] BICYCLIC PIPERIDINE AND PIPERAZINE DERIVATIVES AS GPCR MODULATORS FOR THE TREATMENT OF OBESITY, DIABETES AND OTHER METABOLIC DISORDERS<br/>[FR] DÉRIVÉS DE PIPÉRIDINE ET DE PIPÉRAZINE BICYCLIQUES EN TANT QUE MODULATEURS DE RCPG POUR LE TRAITEMENT DE L'OBÉSITÉ, DU DIABÈTE ET D'AUTRES TROUBLES MÉTABOLIQUES
  申请人：SCHERING CORP

  公开号：WO2010114957A1

  公开（公告）日：2010-10-07

  The present invention relates to Bicyclic Piperidine and Piperazine Derivatives, compositions comprising a Bicyclic Piperidine and Piperazine Derivative, and methods of using the Bicyclic Piperidine and Piperazine Derivatives for treating or preventing obesity, diabetes, a metabolic disorder, a cardiovascular disease or a disorder related to the activity of a GPCR in a patient.

  本发明涉及双环哌啶和哌嗪衍生物，包括含有双环哌啶和哌嗪衍生物的组合物，以及使用双环哌啶和哌嗪衍生物治疗或预防患者的肥胖症、糖尿病、代谢性疾病、心血管疾病或与GPCR活性有关的疾病的方法。
• BICYCLIC PIPERIDINE AND PIPERAZINE DERIVATIVES AS GPCR MODULATORS FOR THE TREATMENT OF OBESITY, DIABETES AND OTHER METABOLIC DISORDERS
  申请人：Boyle Craig D.

  公开号：US20120021976A1

  公开（公告）日：2012-01-26

  The present invention relates to Bicyclic Piperidine and piperazine Derivatives, compositions comprising a Bicyclic Piperidine and piperazine Derivative, and methods of using the Bicyclic Piperidine and piperazine Derivatives for treating or preventing obesity, diabetes, a metabolic disorder, a cardiovascular disease or a disorder related to the activity of a GPCR in a patient.
• US8580807B2
  申请人：——

  公开号：US8580807B2

  公开（公告）日：2013-11-12